Please login to the form below

Not currently logged in

Roche leads pharma R&D spend for 2013

Top 30 pharma companies spent a total of $112bn on research
Roche Basel Switzerland

Roche topped industry spending on R&D in 2013 as pharma's overall research investments rose by $723m, according to a new report.

The Swiss firm, which this week filed a melanoma combination drug for US approval, spent $10bn on research into new products, ahead of rivals such as Novartis, which spent $9.8bn and the $8.2bn spent by Johnson & Johnson (J&J).

GlobalData's PharmaLeaders: Global pharmaceutical benchmark report shows the world's leading 30 pharma companies spent $112bn on research and development in 2013, up $723m over the previous year.

According to Adam Dion, global analyst at GlobalData, this increase in R&D spending was partly due to drug makers advancing their pipeline programmes into later-stage clinical trials.

Despite being outspent by Roche, Novartis and J&J were the two companies to increase their R&D expenditure the most between 2012 and 2013. Novartis increased its spending by 5.6% while the figure was 6.8% for J&J.

Dion said: “Roche's R&D spending was bolstered by continued investment in its oncology and neuroscience therapeutic areas, such as the company's investigational anti-PD-L1 antibody targeting lung cancer, and the advancement of its programmes for Alzheimer's diseases.”

Dion also cited Novartis' R&D spending jump on its Alcon subsidiary, which allocated resources to progress the development of new eye care products.

The report found that a number of leading pharma companies opted to cut R&D spending, including Pfizer, which cut over $1.2bn partly to reduce costs after being hard by patent losses for key drugs.

Merck & Co is also cutting back and is in the middle of a restructuring programme that cut $600m from its clinical operations over the analysed period, a consequence of its respiratory therapy Singular's patent lapse.

Article by
Kirstie Pickering

19th December 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...